TNFRSF8 and classic Hodgkin lymphoma: Brentuximab vedotin, an antibody–drug conjugate targeting CD30, has shown efficacy in patients with relapsed or refractory cHL and is being studied in combination with ICIs to enhance therapeutic outcomes [64,66].